Occurrence of de novo ABL kinase domain mutations in primary bone marrow cells after BCR-ABL gene transfer and Imatinib mesylate selection

被引：0
|
作者：
S Flamant
A G Turhan
机构：
[1] INSERM U362,
[2] Unite de thérapie cellulaire,undefined
[3] Institut Gustave Roussy,undefined
来源：
Leukemia | 2005年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1265 / 1267
页数：2
相关论文
共 50 条
  • [1] Occurrence of de novo ABL kinase domain mutations in primary bone marrow cells after BCR-ABL gene transfer and imatinib mesylate selection
    Flamant, S
    Turhan, AG
    LEUKEMIA, 2005, 19 (07) : 1265 - 1267
  • [2] De novo ABL kinase domain mutations in murine bone marrow cells retrovirally transduced with wild-type p210 BCR-ABL and amplified in culture with imatinib mesylate.
    Flamant, S
    Guillier, M
    Bonnet, ML
    Lecouedic, JP
    Vainchenker, W
    Turhan, AG
    BLOOD, 2004, 104 (11) : 549A - 549A
  • [3] AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE
    Pennisi, M. S.
    Stagno, F.
    Massimino, M.
    Stella, S.
    Di Raimondo, F.
    Messina, A.
    Vigneri, P.
    HAEMATOLOGICA, 2008, 93 : S66 - S66
  • [4] AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE
    Vigneri, P.
    Stagno, F.
    Massimino, M.
    Berretta, S.
    Stella, S.
    Del Fabro, V.
    Messina, A.
    Di Raimondo, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 312 - 313
  • [5] BCR-ABL kinase domain mutations in patient with secondary but not primary resistance to imatinib.
    Al-Ali, HK
    Lange, T
    Krahl, R
    Mueller, C
    Patzer, G
    Niederwieser, D
    Deininger, MWN
    BLOOD, 2002, 100 (11) : 368A - 369A
  • [6] Not all imatinib resistance in CML are BCR-ABL kinase domain mutations
    Wei, Yuan
    Hardling, Mats
    Olsson, Bob
    Hezaveh, Rahil
    Ricksten, Anne
    Stockelberg, Dick
    Wadenvik, Hans
    ANNALS OF HEMATOLOGY, 2006, 85 (12) : 841 - 847
  • [7] Not all imatinib resistance in CML are BCR-ABL kinase domain mutations
    Yuan Wei
    Mats Hardling
    Bob Olsson
    Rahil Hezaveh
    Anne Ricksten
    Dick Stockelberg
    Hans Wadenvik
    Annals of Hematology, 2006, 85 : 841 - 847
  • [8] INCREASING BCR-ABL EXPRESSION LEVELS AND/OR OCCURRENCE OF ABL POINT MUTATIONS NOT ALWAYS PREDICT RESISTANCE TO IMATINIB MESYLATE IN BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
    Grammatico, S.
    Elia, L.
    Vitale, A.
    Matarazzo, M.
    Falciani, V
    Rago, A.
    Cenfra, N.
    Peluso, A. L.
    Pedace, L.
    Grammatico, P.
    Pane, F.
    Meloni, G.
    Foa, R.
    Cimino, G.
    HAEMATOLOGICA, 2008, 93 : S88 - S89
  • [9] Primary imatinib resistance in chronic myeloid leukemia patients in a developing country: BCR-ABL kinase domain mutations or BCR-ABL independent mechanisms?
    Yap, E.
    Tumian, N. R.
    Azma, R. Z.
    Sharifah, N. A.
    Salwati, S.
    Hamidah, N. H.
    Elias, M. H.
    Wong, C. L.
    MALAYSIAN JOURNAL OF PATHOLOGY, 2017, 39 (02) : 107 - 113
  • [10] An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate
    Leguay, T
    Desplat, V
    Lagarde, V
    Marit, G
    Reiffers, J
    Mahon, FX
    LEUKEMIA, 2005, 19 (09) : 1671 - 1673
12345